Abstract:Gemechu Churiso, 1 Gose Husen, 2 Denebo Bulbula, 2 Lulu Abebe 3 1 Department of Medical Laboratory Sciences, Dilla University, Dilla, Ethiopia; 2 Department of Orthopedic Surgery, Dilla University, Dilla, Ethiopia; 3 Department of Psychiatry, Dilla University, Dilla, Ethiopia Correspondence: Gemechu Churiso, Email Antigen-presenting cells recognize respiratory syncytial virus antigens, and produce cytokines and chemokines that act on immune cells. Dendritic cells play the main role in inflammatory cytokine responses. Similarly, alveolar macrophages produce IFN-β, IFN-α, TNF-α, IL-6, CXCL10, and CCL3, while alternatively activated macrophages differentiate at the late phase, and require IL-13 or IL-4 cytokines. Furthermore, activated NKT cells secrete IL-13 and IL-4 that cause lung epithelial, endothelial and fibroblasts to secrete eotaxin that enhances the recruitment of eosinophil to the lung. CD8 + and CD4 + T cells infection by the virus decreases the IFN-γ and IL-2 production. Despite this, both are involved in terminating virus replication. CD8 + T cells produce a larger amount of IFN-γ than CD4 + T cells, and CD8 + T cells activated under type 2 conditions produce IL-4, down regulating CD8 expression, granzyme and IFN-γ production. Antiviral inhibitors inhibit biological functions of viral proteins. Some of them directly target the virus replication machinery and are effective at later stages of infection; while others inhibit F protein dependent fusion and syncytium formation. TMC353121 reduces inflammatory cytokines, TNF-α, IL-6, and IL-1β and chemokines, KC, IP-10, MCP and MIP1-α. EDP-938 inhibits viral nucleoprotein (N), while GRP-156784 blocks the activity of respiratory syncytial virus ribonucleic acid (RNA) polymerase. PC786 inhibits non-structural protein 1 (NS-1) gene, RANTES transcripts, virus-induced CCL5, IL-6, and mucin increase. In general, it is an immune reaction that is blamed for the disease severity and pathogenesis in respiratory syncytial virus infection. Anti-viral inhibitors not only inhibit viral entry and replication, but also may reduce inflammatory cytokines and chemokines. Many respiratory syncytial virus inhibitors are proposed; however, only palivizumab and ribavirin are approved for prophylaxis and treatment, respectively. Hence, this review is focused on immunity cell responses to respiratory syncytial virus and the role of antiviral inhibitors. Keywords: immune cells, respiratory syncytial virus, antiviral inhibitors Respiratory syncytial virus (RSV) is an enveloped negative sense RNA virus that has trans membrane surface proteins like F, G and SH, and non-glycosylated virion matrix protein (M), proteins associated with RNA to form viral nucleocapsid (P, N, L and M2 open reading frame 1), and other proteins that are non-structural viral products (NS1 and NS2). 1,2 It causes lower respiratory tract infection affecting mostly elder people and children. 3,4 The RSV virus has 2 main subtypes; subtype A and B. 5 Luminal columnar cells, especially ciliated cells, can be affected by RSV, and the virus can be shed solely from the apical surface of ciliated cells and spread to neighbouring cells by the cilial beats. 6 RSV G protein interaction with C-X-C Motif Chemokine Receptor 1 (CXCR1) on the cell surface of human amniotic epithelial cells (HAECs) is very important to the pathogenesis of the virus. It contributed to around 50% of RSV infectivity in these cells. CXCR1 is predominantly detected on the ciliated cells, and the percentage of these receptors is varied from person to person. 7 Infected people show symptoms like cough, sneezing, runny nose, fever, decrease in appetite, and wheezing within 4 to 6 days of infection. 8 The virus can cause severe infection that includes bronchitis, pneumonia, inflammation of the small airways in the lung, and is common in children younger than one year of age. Older adults and infants earlier than six months of age may need hospitalization and additional oxygen or intubation. 9 Innate and adaptive immunities are induced during RSV infection. Innate immune cells and other virally infected cells secret inflammatory cytokines, which attract and activate immune cells that induce acute inflammation that helps virus clearance. 3 Cellular immunities are very important to clear the RSV infection; 10 unlike virus-neutralizing antibodies that are induced and suboptimal during initial infection and wanes over time. Despite this, re-infection with the virus is common. Even though cellular immunities are very important for the clearance of the virus, they can cause serious lower respiratory tract bronchitis immune pathogenesis. 11</su -Abstract Truncated-

Type I IFN ineffectively activates neonatal dendritic cells limiting respiratory antiviral T-cell responses

Plasmacytoid Dendritic Cells Engagement By Influenza Vaccine As A Surrogate Strategy For Driving T-Helper Type 1 Responses In Human Neonatal Settings

The specific features of the developing T cell compartment of the neonatal lung are a determinant of respiratory syncytial virus immunopathogenesis

Type I Interferons Protect Neonates from Acute Inflammation Through Interleukin 10–producing B Cells

Dendritic cells regulate T cell immune responses to respiratory syncytial virus

The neonatal anti-viral response fails to control measles virus spread in neurons despite interferon-gamma expression and a Th1-like cytokine profile

Type I interferons and MAVS signaling are necessary for tissue resident memory CD8+ T cell responses to RSV infection

Lack of Cell Cycle Inhibitor p21 and Low CD4+ T Cell Suppression in Newborns After Exposure to IFN-β

MyD88-mediated instructive signals in dendritic cells regulate pulmonary immune responses during respiratory virus infection

Lung dendritic cells in respiratory syncytial virus bronchiolitis

Association of Cytokine Responses with Disease Severity in Infants with Respiratory Syncytial Virus Infection

Differential Role of Anti-Viral Sensing Pathway for the Production of Type I Interferon β in Dendritic Cells and Macrophages Against Respiratory Syncytial Virus A2 Strain Infection

Severity of neonatal influenza infection is driven by type I interferon and oxidative stress

T cell responses are elicited against Respiratory Syncytial Virus in the absence of signalling through TLRs, RLRs and IL-1R/IL-18R

Impaired NK cell antiviral cytokine response against influenza virus in small-for-gestational-age neonates

Contribution of Fcγ receptors to human respiratory syncytial virus pathogenesis and the impairment of T-cell activation by dendritic cells

Enhanced IL-2 in early life limits the development of TFH and protective antiviral immunity

The CD4 T cell response to respiratory syncytial virus infection

Plasmacytoid Dendritic Cell Deficiency in Neonates Enhances Allergic Airway Inflammation Via Reduced Production of IFN-α

Innate and adaptive cellular phenotypes contributing to pulmonary disease in mice after respiratory syncytial virus immunization and infection

Immunity Cell Responses to RSV and the Role of Antiviral Inhibitors: A Systematic Review